In several early attempts, in situ delivery of interferon-gamma (IFN-γ) by viral vectors was applied to enforce the MHC class II expression in glioma cells and enhance the anti-tumor activity of T cells [53, 54]. The gene discussed is IFNG; the disease is central nervous system cancer.